EFL033
Join host Chase Hendrickson, MD, from Vanderbilt University Medical Center, as he discusses a recent JCEM article with Ashok Balasubramanyam, MD, from Baylor College of Medicine and guest expert David Nathan, MD, from Harvard Medical School and Massachusetts General Hospital. The article featured this month, by Edwards et al, was first published online in October 2022 in JCEM: “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study”.
Meet the Speakers
David M. Nathan, MD, is a professor of medicine at Harvard Medical School and is Director of the Diabetes Center and the Clinical Research Center at Massachusetts General Hospital. An internationally acclaimed expert on diabetes, he has led some of the most important studies in the treatment and prevention of diabetes, including the Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Study, Diabetes Prevention Program, and the GRADE study. He was awarded the Outstanding Clinician Award in 2002 and the Outstanding Achievement in Clinical Diabetes Research Award in 2015, both from the American Diabetes Association, and the Distinguished Scientist Award from the National Institute of Diabetes Digestive and Kidney Disease, NIH, in 2010.
Ashok Balasubramanyam, MD, is a professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at Baylor College of Medicine. Dr. Balasubramanyam received his clinical and research training at Baylor and at the Massachusetts General Hospital in Boston. He serves as Vice President for Academic Integration at Baylor and Chief Academic Officer of Baylor-St. Luke’s Medical Center and the Texas Division of the Catholic Health Initiatives network. Dr. Balasubramanyam’s research focuses on the causes of complex metabolic diseases — he holds the Rutherford Chair in Diabetes Research and is known for his work in identifying and characterizing atypical forms of diabetes and disorders of adipose tissue. He is principal investigator of the RADIANT (Rare and Atypical Diabetes Network) project, a consortium funded by the National Institutes of Health to discover and determine the causes of new forms of diabetes, and a member of the Baylor center for the NIH’s Undiagnosed Diseases Network. He has been deeply involved in education at every level of clinical and research training, and currently he serves as Director of Baylor’s Clinical Scientist Training Program. Dr. Balasubramanyam also serves as Chair of the American Board of Endocrinology, Metabolism and Diabetes and a councilor of the American Board of Internal Medicine.
Resources